Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October requested the FDA block compounding pharmacies from producing versions of the drug, saying semaglutide is too complex for others to replicate safely.

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%. Below are highlights of comments by CEO Lars Fruergaard Jorgensen in an interview with Reuters: CONFIRMS THE COMPANY HAS LIFTED US CURBS ON LOWER DOSES OF WEGOVY IN PLACE SINCE MID-2023: "In our guidance for the full year,

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Novo Nordisk A/S posted surging sales of its blockbuster weight-loss treatment Wegovy, reassuring investors after rival Eli Lilly & Co. reported disappointing sales of its obesity treatment last week.

Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.